Trials / Completed
CompletedNCT01474681
Safety and Tolerability of HSC835 in Patients With Hematological Malignancies
A First-in-human, Single-arm, Single-center, Open-label, Proof-of-concept Study to Evaluate the Safety and Tolerability of Infusing HSC835 (LFU835-expanded Umbilical Cord Blood Hematopoietic Stem Cells) in Patients With Hematological Malignancies
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 10 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the safety and tolerability of using HSC835 in patients with hematological malignancies.
Conditions
- Acute Myelocytic Leukemia
- Acute Lymphocytic Leukemia
- Chronic Myelogenous Leukemia
- Myelodysplastic Syndrome
- Chronic Lymphocytic Leukemia
- Marginal Zone Lymphoma
- Follicular Lymphomas
- Large-cell Lymphoma
- Lymphoblastic Lymphoma
- Burkitt's Lymphoma
- High Grade Lymphomas
- Mantle-cell Lymphoma
- Lymphoplasmacytic Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HSC835 |
Timeline
- Start date
- 2012-01-09
- Primary completion
- 2016-10-03
- Completion
- 2016-10-03
- First posted
- 2011-11-18
- Last updated
- 2020-12-30
- Results posted
- 2017-05-12
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01474681. Inclusion in this directory is not an endorsement.